Online Purchasing Account You are logged on as Guest. LoginRegister a New AccountShopping cart (Empty)
United States 

Paroxetine . HCl

Highly potent and selective serotonin uptake inhibitor
 
BML-NS710-0020 20 mg 83.00 USD
 
BML-NS710-0100 100 mg 332.00 USD
Do you need bulk/larger quantities?
 
Paroxetine is a highly potent and selective serotonin (5-HT) uptake inhibitor. It acts by binding to the serotonin transporter (SERT) with high affinity (Ki = 05 nM). In vitro paroxetine competitively inhibits the uptake of 5-HT by rat hypothalamic and cortical synaptosomes with only very weak effects on noradrenaline and dopamine uptake. Paroxetine is in clinical use for the treatment of depression, anxiety and other disorders.

Product Specification

Alternative Name:Paxil®
 
Formula:C19H20FNO3 . HCl
 
MW:365.8
 
CAS:110429-35-1; 78246-49-8; 61869-08-7 (free base)
 
Purity:≥98% (UHPLC)
 
Appearance:White to off-white crystalline solid.
 
Solubility:Soluble in DMSO (25mg/ml).
 
Shipping:Ambient
 
Long Term Storage:Ambient
 
BML-NS710 structure
Please mouse over
BML-NS710 structure

Product Literature References

Comparison of the anticholinergic effects of the serotonergic antidepressants, paroxetine, fluvoxamine and clomipramine: J. Fujishiro, et al.; Eur. J. Pharmacol. 454, 183 (2002), Abstract;
Paroxetine: a review: M. Bourin, et al.; CNS Drug Rev. 7, 25 (2001), Abstract;
Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites: M.J. Owens, et al.; J. Pharmacol. Exp. Ther. 283, 1305 (1997), Abstract; Full Text
Biochemical effects of the antidepressant paroxetine, a specific 5-hydroxytryptamine uptake inhibitor: D.R. Thomas, et al.; Psychopharmacol. 93, 193 (1987), Abstract;

Related Literature

Brochures
Essential Research Tools for Neurodegeneration & Neural Signaling
Essential Research Tools for Neurodegeneration & Neural Signaling
Download as PDF

All new literature pieces

Recommend this page

 
For Research Use Only. Not for use in diagnostic procedures.
Keep in touch

©2017 Enzo Life Sciences, Inc.,